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and comparative treatments. Based on data from the literature
review, approximately 50% of MDS patients are transfusion
dependent across all risk groups. In Germany, between 3800 and
5400 MDS patients needed transfusions in 2005. With an esti-
mated growth rate of approximately 6% per year, MDS will
occur in between 9,800 and 13,900 patients in 2010. Taking into
account 24 erythrocyte concentrates (EC) per MDS patient per
year, 2% to 3% of the whole erythrocyte production in Germany
is allocated to MDS. This calculates to total medical transfusion
costs between 8 and 23.5 million Euro depending on the number
of transfusion-dependent patients and unit costs of EC. CON-
CLUSION: A comprehensive cost-of-illness study covering all
settings of care is necessary to learn about MDS resource con-
sumption and economic consequences. Rational allocation of
blood will be of special public health interest in the future due to
the demographic development in Germany. The increasing scar-
city of blood creates a strong need for therapies which terminate
or reduce transfusion dependency. Due to the fact that innovative
therapeutics for MDS will be available soon, it is important to
evaluate their economic consequences with a special focus on
their blood saving potentials.
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POSITIVE INVESTMENT INTERVAL (PII) AND PAYBACK
PERIOD (PP) OFFER DIFFERENT INTERPRETATIONS IN
HEALTHTECHNOLOGY INVESTMENT DECISIONS: PII IS A
MATTER OF BEING AND PP IS A MATTER OFTURNING
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OBJECTIVES: Investment views have been more or less
neglected in economic evaluations. Fortunately, investments can
be efﬁciently and easily assessed by evaluating the most uncer-
tain feature of investment—Time—from two perspectives. The
innovation, Positive Investment Interval (PII), its estimation and
interpretation are presented here in relation to Payback Period
(PP) with a safety example of Hemophilia A (HA), where the
best safety is achieved using plasma/albumin-free methods
(PFM). METHODS: PII estimates the interval when sc. safety
costs are compensated by the treatment costs of adverse event/
events (AE). PP, on the other hand, estimates the time when the
safety costs become compensated by the AE treatment costs.
RESULTS: Both PII and PP are acceptable if the effectiveness of
treatment options is equal. PII estimates the interval when
investment to e.g. safety offers positive margin. In simple terms,
PII is interval when no security threats should occur, if more
risky treatment is used. Mathematically, PII compares the incre-
mental costs of new minus old therapy (e.g. safety costs) to the
incremental AE costs of old minus new therapy in a given inter-
val (e.g. annual budgeting period). PP is the reversed version of
PII. Stochastic PIIs can be presented in an AE costs-safety costs
plane. In HA case, when base-case PIIs for annual PFM Advate
vs. non-PFM Kogenate investment were 1–7 years depending on
patient’s weight, age, and treatment modality, were PPs 2–11
months. Longer PII, the better and shorter PP, the better. Thus,
PII > PP is usually a potentially good and beneﬁcial investment
depending on the expected time horizons of possible AEs or
other patient security risks. CONCLUSION: PII is related to
e.g. safety need as time and, thus, it has hands-on interpretation
for political debate. PII can be compared to the time intervals of
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OBJECTIVES: Our objective is to develop a quantitative, model-
based protocol simulation approach for evaluating the clinical
and economic effects of adverse drug outcomes related to genetic
variation at early stages of drug or test development, using war-
farin pharmacogenomics as a case-study. METHODS: We im-
plemented a previously published (Hamberg et al. (2007))
population pharmacokinetic/pharmacodynamic (PK/PD) model
of warfarin distribution and effect that incorporates the effects of
genetic variation in the CYP2C9 and VKORC1 genes and other
relevant demographic variables. We simulated outcomes (INR
distribution) of a non-pharmacogenomic-based warfarin dosing
protocol, and plan to simulate various pharmacogenomic-based
dosing protocols and then integrate these results with pharma-
coeconomic simulation models. RESULTS: INRs were modeled
for 500 simulated patients using the same patient demographics
(median and range) as those reported in the Hamberg analysis.
The 5 mg/daily INR nomogram of Kovacs et al. (2003) was
simulated. Baseline INRs were uniformly distributed over a range
of 0.9 to 1.3. The INR at day 6 after initiation of therapy ranged
from 0.97 to 10.31 with a median of 3.61. Median INR grouped
by CYP2C9 expression ranged from 3.17 for *1*1 patients to
5.29 for *3*3 patients. INR variations are linked to the risks of
bleeding and stroke, and ultimately to the pharmacoeconomic
outcomes of costs and quality-adjusted life years. CONCLU-
SION: ‘P-cubed’ (P3) modeling will be feasible only when sufﬁ-
cient population PK/PD data are available and valid long-term
linkages can be made. It may serve as a tool to explore the
robustness of such linkages and probe alternative therapeutic
scenarios. Although our ﬁndings are preliminary to date,
P3-modeling may provide a useful quantitative framework to
help inform pharmacogenomic trial design, regulatory decisions,
and potentially clinical guidelines and reimbursement policies.
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OBJECTIVES: The recent FENOC 2006 comparative trial
reported comparable efﬁcacy for rFVIIa and APCC in the treat-
ment of joint bleeds in hemophiliacs with inhibitors. A literature-
based Bayesian meta-regression analysis was carried out to place
these results within the context of earlier, non-comparative
studies and to identify key variables inﬂuencing treatment efﬁ-
cacy. METHODS: A systematic search of the literature identiﬁed
15 studies reporting usable and relevant data, which were pooled
in a Bayesian random-effects survival model. A repeating Gomp-
ertz hazard function was selected to model an initial increase in
the hazard of bleed resolution after each injection, followed by a
decrease until the next injection was administered. Model cova-
riates included medication type and the combination of the time-
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